TITLE

Antidiabetic Drugs Present and Future: Will Improving Insulin Resistance Benefit Cardiovascular Risk in Type 2 Diabetes Mellitus?

AUTHOR(S)
Campbell, I.W.
PUB. DATE
November 2000
SOURCE
Drugs;Nov2000, Vol. 60 Issue 5, p1017
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Results from the United Kingdom Prospective Diabetes Study showed that intensive treatment of type 2 (non-insulin-dependent) diabetes mellitus, with sulphonylureas or insulin, significantly reduced microvascular complications but did not have a significant effect on macrovascular complications after 10 years. Insulin resistance plays a key role in type 2 diabetes mellitus and is linked to a cluster of cardiovascular risk factors. Optimal treatment for type 2 diabetes mellitus should aim to improve insulin resistance and the associated cardiovascular risk factors in addition to achieving glycaemic control. Treatment with sulphonylureas or exogenous insulin improves glycaemic control by increasing insulin supplies rather than reducing insulin resistance. Metformin and the recently introduced thiazolidinediones have beneficial effects on reducing insulin resistance as well as providing glycaemic control. There is evidence that, like metformin, thiazolidinediones also improve cardiovascular risk factors such as dyslipidaemia and fibrinolysis. Whether these differences will translate into clinical benefit remains to be seen. The thiazolidinediones rosiglitazone and pioglitazone have been available in the US since 1999 (with pioglitazone also being available in Japan). Both products are now available to physicians in Europe.
ACCESSION #
9593251

 

Related Articles

  • Monitoring the Safety of Pioglitazone: Results of a Prescription-Event Monitoring Study of 12 772 Patients in England. Kasliwal, Rachna; Wilton, Lynda V.; Shakir, Saad A. W. // Drug Safety;2008, Vol. 31 Issue 10, p839 

    BACKGROUND: Pioglitazone is an antidiabetic drug that targets insulin resistance in patients with type 2 diabetes mellitus by stimulating the peroxisome proliferator-activated receptor (PPAR)-γ. Pioglitazone belongs to a class of drugs called thiazolidinediones (TZDs) and was launched in...

  • Insulin resistance is independently associated with peripheral and autonomic neuropathy in Korean type 2 diabetic patients. Lee, Kee; Nam, Ji; Ahn, Chul; Hong, Ji-Man; Kim, Seung-Min; Sunwoo, Il-Nam; Moon, Joon-Shik; Na, Sang-Jun; Choi, Young-Chul // Acta Diabetologica;Apr2012, Vol. 49 Issue 2, p97 

    In addition to chronic hyperglycemia, insulin resistance itself has been proposed to cause a diabetic neuropathy. We evaluated the role of insulin resistance in the pathogenesis of peripheral and autonomic neuropathy in patients with type 2 diabetes. Eighty-six patients with type 2 diabetes were...

  • Insulin resistance and the metabolic syndrome. Landsberg, L. // Diabetologia;Jul2005, Vol. 48 Issue 7, p1244 

    This article focuses on the metabolic syndrome. Because the metabolic syndrome is associated with significant cardiovascular risk, and understanding the pathogenesis of this constellation of factors can help define therapeutic strategies to reverse or mitigate the risk. Additional risk factors...

  • Deterioration of Glycemic Control After Long-Term Treatment With Troglitazone in Nonobese Type 2 Diabetic Patients.  // Diabetes Care;Jan2000, Vol. 23 Issue 1, p131 

    Troglitazone is an oral antidiabetic drug used to treat type 2 diabetic patients with insulin resistance. Troglitazone improves overall insulin sensitivity in the liver and skeletal muscles, which are the largest consumers and metabolizers of glucose in the body. Recent reports showed that...

  • Plants and Natural Compounds with Antidiabetic Action. Coman, Cristina; Rugina, Olivia Dumitrita; Socaciu, Carmen // Notulae Botanicae Horti Agrobotanici Cluj-Napoca;2012, Vol. 40 Issue 1, p314 

    Diabetes has become the most common metabolic disease worldwide. In particular, type 2 diabetes is the most commonly encountered type of diabetes, which is characterised by the inability of the organism to respond to normal levels of circulating insulin, also called insulin resistance. Current...

  • Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population. Meisinger, C.; Heier, M.; Loewel, H. // Diabetologia;Feb2005, Vol. 48 Issue 2, p235 

    Aims/hypothesis: To examine gender specific associations between sleep disturbance and incident type 2 diabetes mellitus in a representative population sample in Germany. Methods: The study was based on 4,140 men and 4,129 women (aged 25-74 years) who participated in one of the three MONICA...

  • Why Might Thiazolidinediones Increase Exercise Capacity in Patients With Type 2 Diabetes? LeBrasseur, Nathan K.; Ruderman, Neil B. // Diabetes Care;Dec2005, Vol. 28 Issue 12, p2975 

    This article comments on a study which found that rosiglitazone, a thiazolidinedione commonly used to treat insulin resistance, also improved exercise capacity in patients with type 2 diabetes. It states reasons behind the decrease of exercise capacity in type 2 diabetics. It offers information...

  • Up- and Down-Regulation of Serum Insulin Levels by Pioglitazone in Newly Diagnosed, Drug Naïve Patients with Type 2 Diabetes. Kutoh, Eiji; Wajs, Jan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA162 

    Pioglitazone is known to down-regulate hyperinsulinemia as a result of decreased insulin resistance. However, many patients with type 2 diabetes possess substantially low insulin levels. It is significant to study its effects on insulin levels as well as other parameters with those low insulin...

  • ACT NOW Study. Tripathy, Devjit; Banerji, Mary Ann; Buchanan, Thomas; Kitabchi, Abbas; Mudaliar, Sunder; Musi, Nicolas; Ratner, Robert; Reaven, Peter; Schwenke, Dawn; Defronzo, Ralph // Diabetes;Jun2007 Supplement 1, Vol. 56, pA572 

    Aims: To examine whether pioglitazone (PIO) can prevent/delay the development of type 2 diabetes mellitus in IGT subjects. We present: (i) description of ACT NOW study, (ii) summary of baseline subject characteristics, (iii) comparison of insulin secretion and insulin sensitivity in subjects...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics